Resistance of bacterial pathogens against antibiotics
is declared
by WHO as a major global health threat. As novel antibacterial agents
are urgently needed, we re-assessed the broad-spectrum myxobacterial
antibiotic myxovalargin and found it to be extremely potent against Mycobacterium tuberculosis. To ensure compound supply
for further development, we studied myxovalargin biosynthesis in detail
enabling production via fermentation of a native producer. Feeding
experiments as well as functional genomics analysis suggested a structural
revision, which was eventually corroborated by the development of
a concise total synthesis. The ribosome was identified as the molecular
target based on resistant mutant sequencing, and a cryo-EM structure
revealed that myxovalargin binds within and completely occludes the
exit tunnel, consistent with a mode of action to arrest translation
during a late stage of translation initiation. These studies open
avenues for structure-based scaffold improvement toward development
as an antibacterial agent.